As more CFOs step into the public spotlight by participating in events and conferences, the cost of misspeaking and the importance of leadership alignment on policy are increasing.

Dr. David A. Kessler tested GLP-1 drugs to shed some pounds over seven months and found there was one rather uncomfortable ...

At 12 weeks, weight loss ranged from 2.6% to 11.3%, compared to a gain of 0.2% in the placebo group. Guggenheim analysts were ...

Weight loss drugs, including Wegovy (semaglutide) and Mounjaro (tirzepatide), are becoming increasingly popular among those ...

McDonald’s faces falling visits and shrinking demand as GLP-1 drugs and price fatigue reshape consumer habits.

Pennsylvania Governor Josh Shapiro's office has said it is looking to change eligibility for weight loss drugs as part of its 2025-26 budget plans.

State employees will see a roughly 8% increase in their health care insurance rates this year. IDAHO, USA — Health insurance ...

Find out if Novo's GLP-1 patent expiring in Canada is a mistake or a calculated move. Did the firm lose exclusivity over a ...

Last week researchers at the Max Planck Institute for Metabolism Research mapped a previously unknown “smell‑to‑satiety” ...

A South Korean biotech’s GLP-1 candidate has reduced liver fat in patients with metabolic dysfunction-associated ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

New research links semaglutide and tirzepatide, which are GLP-1 agonists used to treat type 2 diabetes and aid weight loss, ...